Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBER Lot Release Requirement Should Be Eliminated – PhRMA

Executive Summary

The lot release requirement for biologics should be eliminated, the Pharmaceutical Research & Manufacturers of America maintained in comments submitted to the HHS Advisory Committee on Regulatory Reform

You may also be interested in...



Greenwood/DeGette Human Subject Protection Bill Has Support Of ACRO

HHS would be directed to harmonize FDA's clinical trial oversight regulations with the common rule under the Greenwood/DeGette human subject protection bill

Greenwood/DeGette Human Subject Protection Bill Has Support Of ACRO

HHS would be directed to harmonize FDA's clinical trial oversight regulations with the common rule under the Greenwood/DeGette human subject protection bill

Clinical Trial Oversight Training Programs For IRBs Recommended By BIO

Institutional Review Boards need better training for clinical trial oversight, not new rules governing procedures, the Biotechnology Industry Organization suggests

Related Content

UsernamePublicRestriction

Register

PS039689

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel